检索结果-南通市图书馆

mutato<sup>&copy</sup>—A Novel Concept for Curing Cancer

Journal of Cancer Therapy 2020年第2期11卷 55-73页

作者： Ilan Morad Hanan Itzhaki Accelerated Evolution Biotechnologies (AEBi) Ltd. Nes-Ziona Israel

One of the main reasons for developing cancer drug-resistance is the ability of cancer cells to adopt mutations that help them fight the treatments. Cancer cells are very mutagenic. This makes the population of cancer cells in any tumor, or any other cancer cells that come from a distinct origin (one parent cell) highly variable. In some cases, there are already drug-resistant cancer cells at the beginning of the treatment. In other cases, they emerge during the treatment. Treating cancer patients with drugs, or other treatments that attack only one cancer-target would therefore be prone to bad prognosis. In addition, these kinds of treatments would also attack (to a lower degree) non-cancer cells that contain the same targets as the cancer cells. This would lead to adverse effects. Combination therapies, or bispecific drugs could partly solve these problems, but not completely. To address this and other problems, a novel concept for curing cancer, mutato©, was developed. mutato is a personalized medicine concept. The main principal of it is using multiple targeting peptides connected together with a toxin. The main advantage of mutato is that it would lower the probability of the targeted cancer cells to develop drug-resistance due to mutations they possess, and at the same time would lower adverse effects due to avidity effect. Each cancer patient would receive a specific mutato drug perfectly suited to his cancer, based on the expression profile of receptors on the outer membrane of his cancer cells. mutato construct production is easy and rapid. Therefore, the production cost would not be as expensive as with other biological drugs, or other sophisticated cancer treatments. In this article several experiments were performed to show the efficacy of different mutato constructs, and the sustainability of the principals of this concept. The results showed that multi-targeting was better than mono targeting, and that mutato was efficient as a mono treatment in vi

关键词： mutato Multiple Targeting Avidity Effect Toxin Curing Cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：